UK markets open in 34 minutes
  • NIKKEI 225

    26,537.31
    +240.45 (+0.91%)
     
  • HANG SENG

    26,758.35
    +88.60 (+0.33%)
     
  • CRUDE OIL

    45.64
    -0.07 (-0.15%)
     
  • GOLD FUTURES

    1,810.00
    +4.50 (+0.25%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • BTC-GBP

    13,335.28
    -99.66 (-0.74%)
     
  • CMC Crypto 200

    348.16
    -22.36 (-6.03%)
     
  • ^IXIC

    12,094.40
    +57.62 (+0.48%)
     
  • ^FTAS

    3,607.81
    -25.54 (-0.70%)
     

Global Blood Screening Market Analysis 2020-2025 and Impact of COVID-19 on the Industry - Imposed Curfews & Lockdowns Worldwide Led to Stalled Blood Donations and Decreased/Cancelled Collection Drives

Research and Markets
·10-min read

Dublin, July 21, 2020 (GLOBE NEWSWIRE) -- The "Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Blood Screening Market is projected to reach USD 3.5 billion by 2025 from USD 1.9 billion in 2020, rising at a CAGR of 12.8%.

Growth in this market is driven by the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens. Technological advancements and developing economies are expected to present opportunities for growth for players in the blood screening market. However, the need to reduce blood screening prices is a major factor in challenging market growth.

COVID-19 Impact Analysis (2020-2025)

COVID-19 outbreak led to curfews and lockdown worldwide, leading to stalled blood donations, decreased/cancelled collection drives, reduced demand for donated blood and has adversely affected the growth of blood screening market during the forecasted period globally. As stringencies with respect to curfews and social distancing become more liberal, the demand is expected to grow creating a deficit in the market. However, governments globally are taking initiatives to increase the donation during the forecasted period, to meet the sudden rise in demand following the lockdown.

Market Dynamics

Globally, the demand for donated blood is rising because of advancements in healthcare systems and the availability of and need for sophisticated surgical procedures, such as cardiovascular and transplant surgery, trauma care, and therapy for cancer and blood diseases. Blood transfusion is usually prescribed in complicated childbirths to prepare for childhood acute anaemia, trauma, and congenital maternal blood disorders.

Road traffic accidents are another important consideration; blood transfusions are often required in the treatment of injuries arising out of road accidents. Moreover, the rising prevalence of infectious diseases is another major factor driving the demand for effective blood screening (due to the risk of disease transmission during blood transfusion). Rising incidences of such factors are expected to drive the demand for blood transfusions and thereby will drive the growth for the blood screening market.

Emerging markets such as India, China, and Southeast Asia offer promising opportunities for the players in the blood screening industry due to their increasing disposable incomes and improving healthcare infrastructure

However, even though NAT is a superior and most reliable technology available across the globe, it is the most expensive technique in this market. Hence the emerging economies and low- income economies rely on ELISA over NAT. This is a major inhibitor for the growth of the blood screening market for NAT in the current timeframe.

Nucleic Acid Testing (NAT) segment accounted for the larger share of the blood screening market, by technology, in 2019

The blood screening market, by technology, has been segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment dominates the blood screening market, by technology, primarily due to the increasing number of blood donations and the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies. Based on type, the blood screening market for NAT is segmented into transcription-mediated amplification (TMA) and real-time PCR. Among these, the TMA segment accounts for the larger market share due to the higher sensitivity of this assay.

Blood banks to register the highest growth in the blood screening market during the forecast period

Based on end-users, the blood screening market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2019 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing the number of donations worldwide, and growth in government funding to charitable trusts.

North America will continue to dominate the blood screening market during the forecast period

Based on the region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the blood screening market in North America.

Top 5 players in the blood screening market during 2020-2025:

  • F. Hoffmann-La Roche AG (Switzerland)

  • Grifols (Spain)

  • Abbott Laboratories (US)

  • BioMerieux (France)

  • Bio-Rad Laboratories (US)

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Blood Screening Market Overview
4.2 Blood Screening Market, by Product & Service, 2020 vs. 2025 (USD Billion)
4.3 Blood Screening Market: Geographic Growth Opportunities

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Demand for Donated Blood and Rising Number of Blood Donations
5.2.1.2 Rising Prevalence of Infectious Diseases and the Emergence of Newer Pathogens
5.2.2 Opportunities
5.2.2.1 Technological Advancements
5.2.2.2 Emerging Economies
5.2.3 Challenges
5.2.3.1 Need for Reducing Blood Screening Prices
5.3 COVID-19 Impact on the Blood Screening Market
5.4 Adjacent Markets

6 Blood Screening Market, by Product & Service
6.1 Introduction
6.2 Reagents & Kits
6.2.1 Nat Reagents & Kits
6.2.1.1 High Sensitivity and Rising Use of Nat are Boosting Demand for Related Reagents and Kits
6.2.1.2 Enzymes & Polymerases
6.2.1.3 Standards & Controls
6.2.1.4 Probes & Primers
6.2.1.5 Buffers, Nucleotides, and Solutions
6.2.1.6 Labeling & Detection Reagents
6.2.2 Elisa Reagents & Kits
6.2.2.1 Ease of Use and Cost-Effectiveness of Elisa Reagents & Kits will Drive Market Growth
6.2.2.2 Immunosorbents
6.2.2.3 Controls
6.2.2.4 Conjugates
6.2.2.5 Substrates
6.2.2.6 Sample Diluents & Wash Solutions
6.2.3 Other Reagents & Kits
6.2.3.1 Increasing Use of Western Blot Tests and Rapid Tests will Drive the Growth of This Market Segment
6.3 Instruments
6.3.1 Rental Purchase
6.3.1.1 Convenience and Cost-Effectiveness of Renting Instruments Has Resulted in a Greater End-User Preference
6.3.2 Outright Purchase
6.3.2.1 Availability of Government Support will Increase the Outright Purchase of Instruments
6.4 Software & Services
6.4.1 Increasing Adoption of Instruments will Drive the Demand for Related Software and Services

7 Blood Screening Market, by Technology
7.1 Introduction
7.2 Nucleic Acid Testing
7.2.1 Transcription-Mediated Amplification
7.2.1.1 High Sensitivity of These Assays to Support Market Growth
7.2.2 Real-Time Polymerase Chain Reaction
7.2.2.1 Real-Time Pcr Procedures Provide more Accurate and Effective Results as Compared to Conventional Pcr
7.3 Enzyme-Linked Immunosorbent Assay
7.3.1 Chemiluminescence Immunoassay
7.3.1.1 Clia is Ultrasensitive, Automated, and a Good Alternative to Conventional Methodologies
7.3.2 Fluorescent Immunoassay
7.3.2.1 Rising Demand for Safer and Stable Reagents and the Development of Novel Markers to Support the Growth of This Market Segment
7.3.3 Colorimetric Immunoassays
7.3.3.1 Ci Offers Low Sensitivity as it Uses Vulnerable/Limited Signal Amplification Strategies
7.4 Rapid Tests
7.4.1 Rising Awareness About Rapid Tests in Emerging Countries to Drive Market Growth
7.5 Western Blot Assays
7.5.1 Growing Prevalence of Ttis in Developing Countries Has Resulted in the Increased Demand for Western Blot Assays
7.6 Next-Generation Sequencing
7.6.1 Ngs is an Emerging Technology in the Blood Screening Market

8 Blood Screening Market, by End User
8.1 Introduction
8.2 Blood Banks
8.2.1 Blood Banks Hold the Largest Share of the Blood Screening Market
8.3 Hospitals
8.3.1 Increasing G Number of Surgical Procedures will Drive the Growth of the Hospitals Segment

9 Blood Screening Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 the US Dominates the Global Blood Screening Market
9.2.1.2 COVID-19 Impact Analysis
9.2.2 Canada
9.2.2.1 Growing Volume of Surgical Procedures Performed and the High Burden of Cancer to Support Market Growth
9.2.2.2 COVID-19 Impact Analysis
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany is the Largest Market for Blood Screening Technologies in Europe
9.3.1.2 COVID-19 Impact Analysis
9.3.2 France
9.3.2.1 Increasing Prevalence of HIV to Support Market Growth
9.3.3 UK
9.3.3.1 Government Support to Prevent Transmission of HIV and Other Infections will Drive Market Growth
9.3.3.2 COVID-19 Impact Analysis
9.3.4 Italy
9.3.4.1 Italy is Witnessing an Increase in the Number of Blood Donors
9.3.4.2 COVID-19 Impact Analysis
9.3.5 Spain
9.3.5.1 Increasing Adoption of Nat Technology will Support Market Growth
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.1.1 China Has a High Prevalence of Infectious Diseases
9.4.1.2 COVID-19 Impact Analysis
9.4.2 Japan
9.4.2.1 Japan Has Witnessed an Increase in the Adoption of Advanced Blood Screening Technologies
9.4.2.2 COVID-19 Impact Analysis
9.4.3 India
9.4.3.1 Increasing Number of Road Accidents will Support Market Growth
9.4.3.2 COVID-19 Impact Analysis
9.4.4 Australia
9.4.4.1 Rising Number of Blood Donations will Propel Market Growth
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Increasing Incidence of Cancer will Support the Growth of This Market
9.5.2 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Rising Prevalence of Infectious Diseases will Drive Market Growth in the Region

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis, 2019
10.2.1 Market Share Analysis for Nat Blood Screening, 2019
10.2.2 Market Share Analysis for Total Blood Screening, 2019
10.3 Competitive Scenario
10.3.1 Partnerships, Agreements, and Collaborations (2017-2019)
10.3.2 Product Launches (2017-2019)
10.3.3 Expansions (2017-2019)
10.3.4 Acquisitions (2017-2019)
10.4 Competitive Leadership Mapping (2019)
10.4.1 Vendor Inclusion Criteria
10.4.2 Visionary Leaders
10.4.3 Innovators
10.4.4 Dynamic Differentiators
10.4.5 Emerging Companies

11 Company Profiles
11.1 Grifols
11.2 F. Hoffmann-La Roche
11.3 Abbott Laboratories
11.4 BioMerieux
11.5 Bio-Rad Laboratories
11.6 Becton, Dickson and Company
11.7 Danaher Corporation
11.8 Ortho Clinical Diagnostics
11.9 Siemens Healthineers
11.10 Thermo Fisher Scientific
11.11 Diasorin
11.12 GE Healthcare
11.13 Merck KGaA
11.14 Perkinelmer
11.15 Bio-Techne
11.16 GFE
11.17 Trinity Biotech
11.18 J. Mitra Diagnostics Pvt. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ls5zqq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900